Literature DB >> 20861092

Chemotherapy for low-grade gliomas: when? how? how long?

Michael Weller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861092      PMCID: PMC3018930          DOI: 10.1093/neuonc/noq137

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  4 in total

1.  Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.

Authors:  Matthieu Peyre; Stéphanie Cartalat-Carel; David Meyronet; Damien Ricard; Anne Jouvet; Johan Pallud; Karima Mokhtari; Jacques Guyotat; Emmanuel Jouanneau; Marie-Pierre Sunyach; Didier Frappaz; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2010-05-20       Impact factor: 12.300

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Dynamic history of low-grade gliomas before and after temozolomide treatment.

Authors:  Damien Ricard; Gentian Kaloshi; Alexandra Amiel-Benouaich; Julie Lejeune; Yannick Marie; Emmanuel Mandonnet; Michèle Kujas; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antoine F Carpentier; Antonio Omuro; Laurent Capelle; Hugues Duffau; Philippe Cornu; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

4.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

  4 in total
  5 in total

1.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.

Authors:  C Izquierdo; A Alentorn; A Idbaih; M Simó; G Kaloshi; D Ricard; M Barritault; D Meyronet; J Bruna; J Honnorat; J Y Delattre; F Ducray
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

3.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

4.  Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.

Authors:  P Mazzocco; C Barthélémy; G Kaloshi; M Lavielle; D Ricard; A Idbaih; D Psimaras; M-A Renard; A Alentorn; J Honnorat; J-Y Delattre; F Ducray; B Ribba
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-10

5.  Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.

Authors:  Pauline Mazzocco; Jérôme Honnorat; François Ducray; Benjamin Ribba
Journal:  Comput Math Methods Med       Date:  2015-12-15       Impact factor: 2.238

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.